What We Are Focusing on

We will have produced new drugs focusing on the three research areas as shown below.

SHIONOGI focuses on infectious diseases and psychiatric and neurological disorders as our core therapeutic areas. In addition, we are pursuing new growth areas such as cancer and vaccines. In order to meet medical and social needs, we aim to provide total care for the respective disease, including our core breakthrough drugs as well as prevention and other measures. To this end, while focusing on its strengths in small-molecule drugs, SHIONOGI is researching to acquire new therapies such as digital medicine, and technologies to help with diagnosis and prevention.

SHIONOGI, which has core competence in infectious diseases area, is promoting drug discovery research and development with "freedom from the threat of infectious diseases" as one of the important issues (materiality) that the company should aim for. We are conducting research every day to realize total care that meets needs, including acute respiratory infections and chronic severe infections.

One is the correspondence to COVID-19 in recent years, further research on pandemics that may occur in the future, and promotion of research that will help prevent future infectious diseases. These infectious diseases are life-threatening when they become severe, and their rapid spread from person to person will have a huge impact on society and economic activities.　Furthermore, infectious diseases that are difficult to cure with existing drugs and emerging infectious diseases that are difficult to predict when they will occur are also major social and medical needs. In particular, the three major infectious diseases, HIV, tuberculosis, and malaria, pose a huge threat and challenge from the perspective of global health. From the perspective of the SDGs, it is hoped that the problem will be overcome as soon as possible.

To free from the threat of infectious diseases, SHIONOGI will promote the creation of innovative new drugs and take on the challenge of providing total care for infectious diseases through a variety of approaches, including diagnostic agents.

Unmet medical needs for psychiatric and neurological disorders vary from patient to patient, and we are committed to realize a world where people can receive medicines and medical services according to each patients’ need at the right time. With this in mind, we work tirelessly to develop medicines for the treatment of psychiatric and neurological disorders. Since drug development of psychiatric and neurological disorders is extremely challenging, in addition to conventional methods, we are actively seeking imaging and molecular biomarkers to serve as objective indicators.